Introduction {#s1}
============

The clinical validation of key conceptual developments in the field of tumor immunology has engendered much interest in strategies to initiate immune cell function within the tumor microenvironment (TME). Central to effective anti-tumor immunity induced by cancer immunotherapies is the ability to re-educate and re-activate immune effector and cytotoxic T cells to eliminate cancer cells. As such, immunotherapies targeting T cell immune checkpoint receptors cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and/or programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) have ascended to first-line therapies for a number of solid malignancies ([@B1]). Combinatorial anti-tumor efficacy of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) in advanced stage melanoma and renal cell carcinoma (RCC) highlights the importance of targeting multiple immune pathways to unleash a more robust anti-tumor immune response ([@B2], [@B3]). In addition, FDA-approval of pembrolizumab (anti-PD-1) for the treatment of microsatellite instability-hi (MSI-h) and deficient DNA mismatch repair (dMMR) tumors, the first cancer-site agnostic treatment approval, as well as the correlation between tumor mutational burden and survival outcome sheds light on the significance of tumor genetics in initiating an immune response ([@B4]--[@B6]). Similarly, PD-L1 status has been shown to impact therapeutic outcome to PD-1/PD-L1 targeting immunotherapies ([@B7]). This highlights that a better understanding of the immune contexture and its interaction with surrounding tumor, stroma, and their derivatives (e.g., chemokines and other soluble factors) is crucial to developing novel therapeutic targets to efficiently shape and re-condition the TME, reinvigorating the immune response against cancer.

Functional anti-tumor immunity relies on both the quality (effector and cytotoxic function) and quantity (numbers and localization) of tumor-infiltrating lymphocytes (TILs) in the TME. Targeting CTLA-4 and PD-1 non-redundantly mobilizes and activates alternate T cell components, with CTLA-4 shown to inhibit priming and generation of antigen-specific T cells in the lymph nodes whereas PD-1 limits CD8^+^ T cell numbers in the tissue, for superior anti-tumor outcomes ([@B8], [@B9]). The concept of targeting two or more non-redundant immune regulatory pathways for enhanced anti-tumor immunity is not limited to adaptive immunity. A combination of anti-DR5, anti-CD40, and anti-CD137 agonistic antibodies aiming to induce apoptosis in tumor cells, activate antigen presenting cells (innate immunity), and co-stimulate CD8^+^ T cells (adaptive immunity), respectively, has been shown to eradicate both established transplantable and spontaneous tumors ([@B10]). Similarly, it has been shown that a combination of recombinant interleukin (IL)-2, anti-PD-1, a tumor-antigen targeting antibody, and an additional vaccine targeting three individual tumor antigens is able to eradicate a poorly immunogenic murine melanoma, via the activation of both innate and adaptive immunity ([@B11]). Here, we review key approaches to target pathways alternative to mainstream T cell checkpoint receptors to re-educate the TME and alleviate immune suppression and highlight challenges for therapy selection and implementation in the clinic.

Improving Tumor Control With Myeloid Cells In The TME {#s2}
=====================================================

Myeloid cells predominate the TME and in many cases evolve to display an immunosuppressive phenotype and ineffective antigen presenting cells (APCs) due to the inflammatory milieu ([Figure 1](#F1){ref-type="fig"}). Tumor-associated macrophages (TAMs) are innate immune cells of heterogeneous origins that have been shown to accumulate in the TME as tumors progress ([@B12]--[@B14]). The presence of immunosuppressive TAMs can interfere with T cell-mediated anti-tumor immune responses ([@B15], [@B16]). Given the absence of a universal definition for TAMs, we have listed relevant markers used in individual studies. It has been reported that an accumulation of monocyte-derived TAMs (CD11b^lo^ MHC-II^−/lo^) positively correlates with the proportion of tumor-infiltrating exhausted PD-1^+^ CD8^+^ T cells in a mouse model of mammary cancer ([@B12]), illustrating a potential mechanism by which TAMs promote tumor escape by modulating the CD8^+^ T cell response. More recently, it has been shown that TAMs (CD11b^+^ MHC-II^+^) are capable of stripping anti-PD-1 bound to PD-1^+^ T cells by binding to the antibody Fc domain, abrogating the anti-tumor activity of this immune checkpoint inhibitor ([@B17]). It remains unclear if a similar resistance mechanism also exists in the context of anti-PD-L1 therapy. However, in preclinical mouse models Fc engagement is critical for anti-PD-L1 (clone 10F.9G2) therapeutic efficacy by enabling depletion of immunosuppressive TAMs (CD11b^+^ F4/80^+^) ([@B18]). Therefore, defining the functionality of an antibodies Fc region for optimal therapeutic activity in the context of both T cells and myeloid cells is an important consideration. Additionally, modulating TAMs via targeted depletion, inhibiting active migration, and promoting activation and differentiation, as a means to re-educate the TME may increase permissiveness to immune checkpoint inhibitor therapy.

![Immunosuppressive targets in the tumor microenvironment. Re-educating the tumor microenvironment to improve the response to cancer immunotherapies can be performed through targeting many cellular and immunosuppressive factors. These include **(A)** tumor-infiltrating myeloid cells such as tumor-associated macrophages and dendritic cells, **(B)** tumor-infiltrating Tregs, and **(C)** tumor-derived immunosuppressive factors. Therapeutically altering these immunomodulatory components may promote anti-tumor immunity either alone or synergize with FDA-approved immune checkpoint inhibition.](fimmu-11-01633-g0001){#F1}

The colony stimulating factor 1 (CSF1)/CSF1 receptor (CSF1R) axis is crucial for TAM differentiation ([@B19]). Selective depletion of TAMs by targeting CSF1R using monoclonal antibodies or small molecule inhibitors has been shown to restrict CSF1R^+^ TAM accumulation in the TME, leading to reduced tumor growth in a number of mouse models ([@B20]--[@B23]). Depletion of CSF1R^+^ TAMs demonstrated efficacy in improving a wide range of existing cancer therapies, including chemotherapy, oncogene-targeted therapy, and immunotherapy ([@B21], [@B23], [@B24]). In preclinical BRAF-mutant melanoma, co-administration of PLX3397 (CSF1R inhibitor) together with PLX4720 (mutant BRAF inhibitor) effectively sensitizes a PD-1-resistant tumor model to anti-PD-1/PD-L1 therapies ([@B23]). However, CSF1R inhibition induces the expansion of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) that may abrogate the efficacy of combination CSF1R inhibition and anti-PD-1 treatment ([@B23], [@B25]). Evidence that targeting CSF1R and CXCR2 signaling to inhibit TAM and PMN-MDSC expansion, respectively, alongside anti-PD-1 facilitates improved anti-tumor immune responses than either doublet combination ([@B25]). Alternatively, targeting the CCL2/CCR2 axis, a key chemokine pathway involved in macrophage migration to inflammatory sites, to limit their entry into the TME enabled numerical and functional improvement of intratumoral lymphocyte infiltrate ([@B26]--[@B29]). Wu et al. demonstrated improved survival outcomes in cutaneous T-cell lymphoma-bearing mice treated with a CCR2 inhibitor and anti-PD-1 ([@B28]). Collectively, these studies highlight that inhibition of pro-tumor TAMs in the TME reinvigorates the anti-PD-1-driven T cell response. Of note, a phase I/II clinical trial accessing the combinatorial effect of nivolumab, GVAX (a cancer vaccine expressing GM-CSF) and BMS-813160 (a CCR2/CCR5 dual antagonist) in pancreatic ductal adenocarcinoma (PDAC) is currently underway (NCT03767582).

It is worth highlighting that not all tumor-infiltrating myeloid cells promote tumor growth. The production of CXCL9 and CXCL10, predominantly by TAMs (CD11b^+^ Ly6C^int^ CD11c^+^ F4/80^+^), enhances CD8^+^ T cell infiltration and tumor control in response to combination anti-PD-1 and anti-CTLA-4 in a mouse model of mammary adenocarcinoma ([@B30]). High production of these chemokines within the TME is associated with better survival outcomes in melanoma patients receiving combination treatment ([@B30]). In light of these findings, reprogramming these innate immune cell subsets may be beneficial due to their antigen presenting properties promoting infiltration of an effective anti-tumor T cell response. In KPC (LSL-Kras^G12D/+^;LSL-Trp53^R172H/+^;Pdx-1-Cre) PDAC TAMs (CD11b^+^ Gr1^−^ F4/80^+^) enable T cell exclusion and consequently, resistance to immune checkpoint therapy is likely driven by the absence of effector T cells that can be modulated ([@B31], [@B32]). Independent studies of mouse pancreatic models have demonstrated the remodeling activity of the agonistic CD40 antibody by overcoming T cell exclusion in the TME, leading to improved therapeutic response to anti-CTLA-4, and/or anti-PD-1 ([@B33]--[@B35]). Using a T cell-rich but anti-PD-1 resistant mammary carcinoma model, we have recently demonstrated that IL-12 induced by an agonistic CD40 antibody could render terminally exhausted PD-1^hi^ tumor-infiltrating CD8^+^ T cells into their PD-1^int^ progenitor state ([@B36]), leading to improved anti-tumor immunity in response to anti-PD-1 following sensitization by anti-CD40 agonism.

An additional therapeutic approach to re-educate the TME and bolster the efficacy of immune checkpoint therapy is combination treatment with FMS-like tyrosine kinase 3 ligand (FLT3L) and poly I:C treatment, to expand and enhance maturation of anti-tumor CD103^+^ dendritic cells (DCs) resulting in a dramatic increase of intratumoral T cells ([@B37]). Notably, T cell-activating IL-12 producing CD103^+^ DCs diminish over time ([@B37]--[@B41]), suggesting that they may facilitate tumor control during tumor initiation. Beavis et al. also reported a role for anti-PD-1/CTLA-4 activated CD4^+^ Foxp3^−^ cells in enhancing IL-12 production by CD103^+^ DCs, which in turn promoted T cell-mediated anti-tumor immunity in mice ([@B42]). The persistence of intratumoral stimulatory DCs (CD103^+^ BDCA-3^+^) defined by gene expression profiles corelated with improved overall survival outcomes and was associated with higher TIL measurements in metastatic melanoma ([@B43]). Mediating the abundance of intratumoral stimulatory DCs was the presence of tumor-infiltrating natural killer cells and expression of FLT3L, together these components may assist in determining anti-PD-1 therapeutic response and identify therapeutic strategies to potentiate efficacy ([@B43]). More recently, a cluster of DCs named mregDCs (mature DCs enriched in immunomodulatory molecules) co-expressing immunoregulatory genes (*Cd274, Pdcd1lg2*, and *Cd200*) and maturation genes (*Cd40, Ccr7*, and *Il12b*) was found in single cell analysis of mouse and human non-small cell lung cancer (NSCLC) DC infiltrate ([@B44]). Of note, neutralizing IL-4 was shown to enhance mregDC IL-12 production, repressing lung adenocarcinoma in mice ([@B44]). With advances in high-throughput single-cell analysis to provide fine-detail of immune infiltrate in tumors, it is likely to facilitate an expansion of our repertoire of novel targets that will assist to re-educate DCs and other myeloid cells specifically in the TME.

Re-Educating Suppressive and Unconventional T Cells In The TME {#s3}
==============================================================

Regulatory T cells (Tregs) serve as a barrier to limit inflammation, however, their enrichment in the TME of established cancer correlates with poor prognosis and a dampened anti-tumor immune response ([Figure 1](#F1){ref-type="fig"}). Clinical studies have resolved that a higher effector/Treg ratio is associated with favorable outcomes in multiple solid cancers ([@B45], [@B46]). In addition to Treg-induced suppression of effector T cells by manipulating their migration, activation, functionality and/or survival ([@B47], [@B48]), Tregs are able to form an immunosuppressive barrier capable of limiting the trafficking of activated antigen-specific CD8^+^ T cells into the TME ([@B49]). Importantly, Foxp3^+^ Tregs promote effector CD4^+^ and CD8^+^ TIL dysfunction, with improved cytokine-producing capacity upon Treg depletion and reinvigorated T cell responses to immune checkpoint blockade ([@B50]--[@B52]). However, systemic Treg depletion introduced transiently can still increase susceptibility of mice to autoimmunity ([@B53]), indicative that identifying an appropriate target to specifically remove intratumoral Foxp3^+^ Tregs will be advantageous for maintaining therapeutic safety.

Intratumoral Foxp3^+^ Tregs are highly suppressive, with an activated phenotype marked by the expression of several classes of immune receptors \[ENTPD1 (CD39), CTLA-4, OX40, and GITR\], and chemokine receptors (CCR4). Studies using preclinical mouse models showed that anti-CTLA-4 (clone 9H10, 9D9, and H11; antagonist), anti-OX40 (clone OX86; agonist) and anti-GITR (clone DTA-1; agonist) exhibited varying levels of intratumoral Treg depleting activity *in vivo* that was critical to their efficacy ([@B54]--[@B59]). Anti-CTLA-4 (clone 9D9, mouse IgG2a) and anti-OX40 were shown to specifically deplete intratumoral Tregs but not peripheral Tregs ([@B56], [@B57]). Tumor-infiltrating Treg depletion by anti-CTLA-4 enhanced anti-PD-1 sensitivity to the previously resistant AT3 mouse mammary carcinoma ([@B36]). In the clinic, mogamulizumab (an anti-human CCR4 antibody, engineered for ADCC activity) was developed to specifically deplete CCR4^+^ suppressive Tregs found in the TME ([@B60]), and is undergoing testing in combination with T cell checkpoint targets in Phase I/II clinical trials (NCT02301130, NCT02705105, NCT02476123, and NCT02946671). While it remains unclear whether combining anti-CCR4 and anti-PD-1 provides favorable survival benefits, an increase in the proportion of CD8^+^ T cells and a reduction in activated Foxp3^hi^ Tregs was observed in TILs from patients, along with an acceptable safety profile \[([@B61]); NCT02476123\]. With advances in antibody engineering, we should expect refinement of antibodies for both existing and novel targets to modulate TME-specific Tregs to enhance anti-tumor immunity ([@B51], [@B62], [@B63]). Revisiting targeting CD25-expressing Tregs, Vargas et al. found that by altering the IgG backbone (from rat IgG1 to mouse IgG2a) greater specificity was afforded toward intratumoral Treg depleting activity by an Fc-optimized version of CD25 antibody ([@B64]). Anti-CD25-mediated intratumoral Treg depletion synergized with PD-1 blockade therapy in a number of mouse cancer models ([@B64]), highlighting the importance of remodeling the Treg dynamics within the TME to enhance checkpoint blockade therapy. Translation of this combination needs to be thoroughly examined, to limit the depletion of alternate CD25-expressing cell types including effector T cells and NK cells.

Given the critical role of Tregs in maintaining immune homeostasis, attenuating intratumoral Treg suppressive function may be a safer approach to remodel the TME while minimizing the risk of systemic autoimmunity. Studies from a series of experimental modeling showed that the disruption of Foxp3, the critical transcription factor to maintain Treg lineage, altered their suppressor function ([@B65]--[@B67]). This also resulted in the generation of pathogenic effector T cells ([@B67], [@B68]). However, disruption of intratumoural Treg suppressive function has been shown without the loss of its Foxp3^+^ Treg identity. Neuropilin-1 (NRP1) appears crucial to maintain intratumoural Treg stability without aberrant loss of Foxp3 identity, and anti-NRP1 displayed therapeutic efficacy in suppressing tumor growth ([@B69]). Notably, using a co-transfer model of NRP1-intact and NRP1-deficient Tregs, interferon (IFN)-γ produced by NRP1-deficient Tregs is capable of causing fragility to the suppressive capacity of NRP1-intact Tregs, resulting in improved host anti-tumor immunity ([@B70]). Similar to the role of NRP1 to maintain Treg stability, the histone H3K27 methyltransferase enhancer of zeste homolog 2 (EZH2) has been recently shown to be critical for the maintenance of activated Foxp3^+^ Tregs ([@B71]). EZH2 inhibition destabilizes Foxp3 expression and inhibits tumor growth *in vivo* ([@B72], [@B73]). While targeting these pathways may be able to provide an opportunity to dismantle Treg suppression within the TME, these therapies still lack specificity to this cell type. Understanding the role of these molecules in multiple cell types and disease settings is likely to dictate their applicability for utility in cancer immunity.

Besides Tregs, unconventional T cells have also received considerable interest in tumor immunology for their immunoregulatory role. In contrast to CD8^+^ and CD4^+^ T cells that interact with MHC class I and II molecules, unconventional T cells such as natural killer T (NKT) cells interact with non-classical MHC CD1d molecules ([@B74]). α-GalCer (a glycoplipid molecule derived from a marine sponge extract) is a known ligand for NKT cells, and has been widely used to experimentally modulate NKT cells ([@B75]). α-GalCer-activated NKT cells are capable of producing high levels of cytokines (including IFN-γ and IL-21), anti-tumor effector and cytotoxic molecules (perforin and granzymes), and elicit direct tumor lysing properties ([@B76]--[@B78]), which assists to alleviate immunosuppression and enhances DC maturation, leading to improved anti-tumor T cell immunity ([@B79]--[@B81]). Song et al. demonstrated that NKT cells specifically kill monocytes pulsed with neuroblastoma cell lysate and reduce tumor-infiltrating monocytes in a non-classical MHC-dependent manner ([@B82]), highlighting a role for NKT cells in shaping the immune infiltrate in the TME. Studies in mice reported superior anti-tumor activity when α-GalCer therapy to drive NKT cell activity was combined with anti-PD-1 ([@B83], [@B84]). However, most clinical trials assessing the anti-tumor effect of α-GalCer-related compounds have not yet yielded promising outcomes ([@B74]). Discoveries of novel NKT cell agonists (β-mannosylceramide) and improved α-GalCer analogs (α-C-GalCer) ([@B74], [@B85]), as well as greater understanding of tumors where this cell type is prominent may assist in harnessing the potential of NKT cells to improve T cell checkpoint therapy.

Mucosal-associated invariant T (MAIT) cells are another class of unconventional T cell that have gained much attention, given their relative abundance in humans and their association to a number of inflammatory diseases ([@B74]). MAIT cells primarily recognize a number of microbial vitamin B metabolites (such as riboflavin metabolized to 5-OP-RU) ([@B86]--[@B89]) presented by the unconventional non-polymorphic MHC I-like molecule, MR1 ([@B90]). Additional MR1-independent IL-12/18-induced activation has been reported ([@B91], [@B92]). Upon activation, MAIT cells are capable of producing cytokines \[(IL-17, IL-2, IFN-γ, and tumor necrosis factor (TNF)\], proliferate and gain cytotoxic function ([@B93]--[@B95]). In the absence of defined tumor antigens binding to tumor-derived MR1, it is reasonable to speculate that MAIT cells may be regulated by microbial antigens and may be more frequent in tumors with a microbial presence. Circulating levels of MAIT cells were reduced in patients with mucosal-originated cancers (gastric, colon, and lung), but appeared normal in patients with breast, liver, or thyroid cancer ([@B96]). In colon cancer patients, MAIT cells were shown to be preferentially enriched in the TME in comparison to unaffected tissue ([@B96]--[@B99]). Poor survival prognosis has been associated to increased levels of tumor-infiltrating MAIT cells in colon cancer patients ([@B98]). In contrast, MAIT cells did not show a correlation to patient survival in esophageal adenocarcinoma ([@B100]). In concordance with the activation of MAIT cells (TCR-MR1 or IL-12/18 cytokine), they likely elicit direct (MAIT cell to tumor cell) and indirect (MAIT cell to non-MAIT cell or IL-12/18 cytokine competition) effects, regulating host anti-tumor immunity in a TME-specific manner ([@B74], [@B101]). Yan et al. recently reported MR1-deficient mice (which lack MAIT cells) showed improved anti-tumor immunity when assessed using models of experimental lung metastasis, subcutaneous tumor growth, and *de novo* carcinogenesis ([@B102]). In light of these findings, a further assessment of MAIT cells in the cancer setting and their relationship to prognosis and therapeutic outcome should be determined. In addition, given a great interest in microbial modification of the TME ([@B103]--[@B105]) determining whether microbes can be used to initiate metabolic functions that promote anti-tumor immunity is also of interest.

Limiting Immunosuppressive Factors In The TME {#s4}
=============================================

As well as initiation of immunosuppression by immune cell subsets, the tumor itself produces a range of molecules to enable tumor progression and facilitate immune escape ([Figure 1](#F1){ref-type="fig"}). Many of these are soluble factors that prevent overzealous inflammation during tissue damage and infection, however also mediate tumor immune evasion. Transforming growth factor (TGF)β plays an essential role in mediating immune homeostasis, however, in the context of tumor, TGFβ has been shown to both directly promote tumor progression and initiate a broad range of immune responses. These include enhancing suppressive myeloid cell infiltrate ([@B106], [@B107]), disabling NK cell function, and promoting transition to group 1 innate lymphoid cells in the TME ([@B108]), as well as altering the functionality of effector T cell populations while promoting Treg immune suppression ([@B109]--[@B111]). SMAD-3, which acts downstream of TGFβ1 signaling, directly induces PD-1 expression in adoptively transferred tumor antigen-specific CD8^+^ T cells isolated from the TME ([@B112]). This suggests that PD-1-upregulation that facilitates tumor immune escape may in part be dependent on TGFβ. In addition, TGFβ is associated with excluding CD8^+^ T cell entry into the tumor core, which is known to diminish immunotherapy efficacy ([@B113]). Correspondingly, *TGF*β*1* gene expression is significantly higher in patients that show stable or progressive disease, compared to those with complete or partial responses ([@B113]). Targeting TGFβ and therapies directed toward PD-1/PD-L1 or CTLA-4 amplifies tumor control by enabling a robust T cell response with improved CD4^+^ and CD8^+^ T cell activation and CD8^+^ T cell cytokine and cell killing capacity ([@B113]--[@B116]). By inhibiting TGFβ in combination with PD-1/PD-L1 blockade, CD8^+^ T cells also display enhanced capacity to infiltrate the tumor periphery and core, promoting T cell inflammation, and resolving T cell exclusion ([@B113], [@B117]). This highlights that targeting TGFβ may be most effective in tumor types in which TGFβ signaling mediates immune exclusion from the TME.

Impeding the clinical utility of pan-TGFβ inhibitors (blocking isoforms TGFβ1,−2, and−3) is the potential for significant toxicity, particularly pertaining to cardiac function. Development of galunisertib (LY2157299), a TGFβRI inhibitor, has shown promise for both its anti-tumor activity and ability to modulate the TME to provide improved anti-tumor control to immunotherapies ([@B118]). However, due to toxicity concerns, intermittent administration of galunisertib has been performed in clinical trials \[([@B119]) NCT01246986\]. Whether intermittent drug exposure provides selective pressure for tumor escape is unclear. As TGFβ1 appears to be the predominantly enriched in human cancers, targeting this isoform specifically may prove advantageous. Development of TGFβ1-specific inhibitors that promote synergistic anti-tumor immune responses when combined with anti-PD-1, but lack cardiovascular pathologies have been identified and may lead to greater clinical utility ([@B120]). Downstream targets of tumor-derived TGFβ activation may also be more desirable and in some cases are already being assessed for therapeutic potential alongside immune checkpoint inhibitors and other immunomodulatory compounds in the clinic.

Angiogenesis in the TME is an important component to enable nutrient accessibility and maintain tumor growth, this is driven in part by TGFβ induction of vascular endothelial growth factor (VEGF). While VEGF inhibitors have been approved for a number of indications in both oncology and vascular-related diseases, in the cancer setting interest in both anti-angiogenic and immunomodulatory properties for this target are increasing. Notably, VEGF-A promotes inhibitory checkpoint expression and transcriptional reprogramming relating to exhaustion in CD8^+^ T cells ([@B121], [@B122]). TOX, the transcription factor that mediates CD8^+^ T cell exhaustion, was shown to be tightly regulated by VEGF-A ([@B122]). In addition, both VEGF-A and TOX expression levels were significantly reduced in MSI-h colon cancer patients compared to patients with microsatellite stability ([@B122]). MSI-h patients have better survival outcomes in response to cancer immunotherapies, which is predominantly attributed to higher tumor mutational burden ([@B123], [@B124]), but may also be in part be due to reduced angiogenic factors and relieved T cell exhaustion. By combining VEGF-targeted therapies and anti-PD-1, improved anti-tumor immune response was achieved ([@B121], [@B122]). However, TGFβ and VEGF are not completely redundant, and co-targeting these molecules together either therapeutically or through tumor-specific genetic ablation provides additional therapeutic benefit to overcome immune tolerance in the TME ([@B125]). As clinical cohorts involving combination VEGF/TGFβ and immune checkpoint blockade treatment mature, determining which patients respond to this therapy, but also which patients are refractory and the mechanism that initiates tumor escape is of importance.

Generation of immunosuppressive adenosine limits anti-tumor immunity ([@B126]). Both CD39, which catabolizes ATP to AMP, and CD73, the enzyme that generates adenosine from ATP, are expressed by and relate to poor prognosis in a number of cancer types ([@B127]--[@B130]). Regulation of tumor-derived CD73 remains complex with multiple mediators identified, including TGFβ ([@B131], [@B132]). Additional evidence that CD73 expression is driven by adenosine-sensing through host-A2A adenosine receptor (A2AR) expression ([@B133], [@B134]), TNF ([@B135]), and hypoxia within the TME ([@B136], [@B137]). In melanoma, CD73 levels have been linked to low MITF expression and highly invasive tumors ([@B135]). CD73 expression appears to increase with adaptive resistance in anti-PD-1-treated melanoma patients as well as MART-1 adoptive T cell therapy ([@B135]), suggesting that tumor expression may facilitate therapeutic resistance in response to active anti-tumor immunity. In melanoma patients with innate therapeutic resistance, CD73 is not present or induced with exposure to anti-PD-1 treatment ([@B135]), likely due to a lack of inflammatory stimuli in the TME. Therapies targeting the adenosinergic pathway have been shown preclinically to potentiate the response of chemotherapies ([@B127]), immune checkpoint inhibitors ([@B138], [@B139]), chimeric antigen receptor T cells ([@B140]) and oncogenic BRAF inhibitors ([@B141]). This can also be through indirectly targeting the adenosine pathway, with both systemic oxygenation which relieves hypoxia-driven adenosine production, and blockade of an alternate mechanism of adenosine-production by inhibiting CD38, with both shown to potentiate the therapeutic efficacy of immune checkpoint blockade ([@B137], [@B142], [@B143]). Similarly, targeting upstream CD39 has been shown preclinically to promote therapeutic activity of immune checkpoint inhibitors ([@B144]), chemotherapies ([@B145]), and even can potentiate CD73 blockade in suboptimal concentrations ([@B146]). This highlights the complex regulatory network and the multi-faceted combination strategies involving adenosine-related molecules that may add benefit to patient care.

Targeting adenosine production and signaling have both moved forward to early phase clinical trials with promising results (NCT02403193, NCT02503774, NCT03454451). Notably, citforadenant (an A2AR inhibitor) in combination with atezolizumab (anti-PD-L1) initiated therapeutic response in both patients naïve to immunotherapies and those refractory to prior immunotherapy exposure, highlighting the potential for this combination to reinvigorate anti-tumor immunity ([@B147]). Analysis of tumor biopsies from renal cell carcinoma (RCC) preceding therapeutic intervention revealed an adenosine signature that may predict patients who will benefit from adenosine-related therapies ([@B147]). The adenosine signature was consistent with myeloid inflammation and reduced angiogenesis, both of which have been defined as poor prognostically for atezolizumab and sunitinib (tyrosine kinase inhibitor) treatment. This identifies a patient group for which adenosine may be most applicable, that inadvertently are less responsive to current clinically approved therapies for RCC. In addition, an extended disease control rate in response to citforadenant, with or without atezolizumab, was linked to improved CD8^+^ T cell infiltration ([@B147]). Adenosine has previously been shown to limit the proliferation and maturation of lymphocytic immune cell subsets ([@B126], [@B134]), and increased immune infiltrate in to the tumor core has been observed in response to co-targeting CD73 and A2AR in preclinical models ([@B133]). Understanding the regulation of the adenosinergic pathway in particular tumor types and in response to cancer therapies, including immunotherapy, may identify patient populations where adenosine-related therapies may be implemented with greatest success.

With increasing examination of the TME it is clear that a number of therapeutic regimens may be successfully repurposed in the treatment of cancer. For instance, targeting adenosine has been utilized previously in the setting of neurodegeneration, but has increasingly shown merit for initiating anti-tumor immunity. Additionally, aspirin may provide a combinatorial approach to overcome therapeutic resistance to immune checkpoint inhibitors. Increasing evidence demonstrates that cyclooxygenase (COX)-driven production of prostaglandins mediates anti-PD-1 resistance and limits the proinflammatory tumor milieu ([@B148]). COX enzymatic activity is disrupted by high-dose aspirin, which valuably may be repurposed to the cancer setting alongside immunotherapies to promote anti-tumor immunity. Regular aspirin users with colorectal cancer patients displaying low tumor PD-L1 expression are also afforded significantly improved survival outcomes ([@B149]). This survival advantage was not identified in PD-L1 high tumors, suggesting that engagement of the PD-1/PD-L1 axis in the TME may abrogate aspirin-mediated anti-tumor benefit and the potential utility of combination treatment. Genetic ablation of prostaglandin-endoperoxide synthase 2 (*PTSG2)*, which encodes COX-2, has been shown to promote CD8^+^ T cells and decrease the frequency of Tregs within the TME ([@B150]), both of which are predictive markers of good prognosis. Induction of COX-2 may be in part regulated by TGFβ, highlighting the complex nature of direct and indirect regulatory pathways that the tumor elicits to subdue the anti-tumor immune response. Clinical trials to develop an understanding of prostaglandin/COX-2 inhibition and immune checkpoint blockade therapeutic responses are underway in multiple tumor types \[([@B151]) NCT03396952, NCT03638297, NCT03864575, NCT03926338\].

Implementing Combination Therapeutic Regimens {#s5}
=============================================

While preclinical studies have identified a number of clinically relevant therapeutic strategies to reinvigorate the immune response against cancer, their successful clinical utility has been difficult to implement ([Figure 2](#F2){ref-type="fig"}). Combining indoleamine 2,3-dioxygenase (IDO) inhibition, an enzyme upregulated in human cancers that initiates the breakdown of tryptophan leading to multi-faceted immunosuppression within the TME ([@B152]), alongside immune checkpoint inhibitors showed promise for enhancing anti-tumor immunity in mice ([@B153], [@B154]). However, in a phase 3 clinical trial assessing the survival benefit for stage III/IV unresectable melanoma patients treated with epacadostat (selective IDO1 inhibitor) and pembrolizumab (anti-PD-1), this combination failed to provide additive therapeutic potential compared to pembrolizumab alone ([@B155]). Improved understanding of the TME is necessary to assist rational selection of immunotherapies required for optimal treatment outcomes. Of course, this remains a challenge even for clinically approved agents, where aside from tumor PD-L1 expression and genetic stablility of the tumor, no biomarkers for efficacy or toxicity of immune checkpoint inhibitors are approved for clinical use. Significant investment to establish biomarkers to denote responders and non-responders should be performed in early phase clinical trials to identify subgroups for which combination therapies may show greatest activity, an important first-step to facilitate response, mitigate toxicity, and minimize unnecessary cost.

![Growing challenges in the implementation of immunotherapeutic strategies. Decision-making for the most efficacious immunotherapeutic combination for cancer patients presents multiple layers of challenges. These include those surrounding the patient\'s tumor microenvironment, the potential risk for initiation of immunotoxicities, and the sequence for appropriate timing of therapeutic interventions. Surrounding each of these challenges are multidimensional considerations that relate to improving anti-tumor immunity and targets that influence the selection of immunomodulatory agents.](fimmu-11-01633-g0002){#F2}

In the same vein, examining optimal timing for immunotherapeutic combinations is often not well-defined. In most cases, therapeutic benefit for novel clinical agents are tested either alone or alongside concurrent anti-PD-1/PD-L1 treatment, often in cancer patients refractory to previous immune checkpoint inhibitor exposure. Preclinical evidence suggests synchronous administration of multiple immunotherapies can in some circumstances be detrimental. Two independent studies identified that concurrent administration of anti-OX40 to anti-PD-1 therapy either with or without a tumor vaccine diminished the anti-tumor immune response compared to addition of anti-OX40 alone in preclinical mouse models ([@B156], [@B157]). Notably, staggering the timing of these therapies where anti-OX40 preceded anti-PD-1 treatment facilitated greatest tumor control ([@B156]). Using a preclinical PDAC model, the use of gemcitabine and nab-paclitaxel, a standard chemotherapy combination for PDAC, impaired the efficacy of anti-CD40, anti-PD-1, and anti-CTLA-4 ([@B34]). Additionally, transient treatments preceding immune checkpoint inhibition can also significantly re-educate the immune response to promote anti-tumor immunity. In an anti-PD-1-resistant mouse model, a single-dose of agonistic anti-CD40 sensitized the TME to anti-PD-1 treatment in a synergistic manner ([@B36]). Strongly activating or agonistic therapies may provide greatest benefit as sensitizing agents to remodel the TME and promote entry of anti-tumor immune cells that are then targetable by immune checkpoint blockade. Alternating timing of treatments or reducing the therapeutic window for largely inflammatory combinations may also assist to potentiate therapeutic response and minimize immunotherapy-induced immune-related adverse events (irAEs).

Challenges For Re-Educating The TME {#s6}
===================================

With the advent of high-throughput screening to delineate critical components that prevent immune infiltrate or disable active anti-tumor immunity, a growing understanding of rational targets to re-ignite a therapeutic response is becoming increasingly available ([@B158]--[@B161]). This aims to equip patients who develop adaptive or acquired resistance with greater tools to re-engage the immune response against cancer and for patients with innate resistance to enable visibility of tumors ([@B162], [@B163]). New subgroups of cancer patients that present distinct challenges to the efficacy of immunotherapies are emerging. Of growing interest, is the relationship between metastatic site and therapeutic outcome, in which liver metastasis appears to be a major obstacle even for combination anti-PD-1 and anti-CTLA-4 treatment ([@B164], [@B165]). Most prominently, melanoma patients bearing liver metastasis have reduced CTLA-4 and PD-1 co-expression in CD8^+^ T cells ([@B164]), which has been shown to stratify therapeutic response to immune checkpoint inhibitor treatment ([@B166]). Efforts to provide mechanistic insight as to whether therapeutic resistance is due to myeloid cell dysfunction, Treg suppression, and immunosuppressive factors accumulating in the TME are essential, highlighting the need for tailored immunotherapies.

As the number and type of combination immunotherapies expands, the risk for increasing irAEs may also become more prevalent. Combination nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) clearly exhibits greater levels of severe grade 3-4 immunotoxicities than either therapy alone ([@B3], [@B167]). Surprising levels of irAEs have been observed with other rational combinations. For instance, targeted therapies (such as BRAF inhibitors and MEK inhibitors) have been shown to potentiate immune checkpoint inhibitor activity in preclinical models ([@B168]), but when used together in melanoma patients severe irAEs were observed forcing closure of the study ([@B169], [@B170]). This highlights a need for improved preclinical models that emulate clinical conditions and allow for simultaneous assessment of tumor control and development of irAEs ([@B171]). Developing tumor models in autoimmune-prone mice or lowering the threshold for self-tolerance in mice with available syngeneic tumors that are resistant to autoimmune responses may facilitate improved therapeutic modeling ([@B53], [@B171], [@B172]). With the expanding use of cancer immunotherapies in more diverse populations of cancer patients, including those with pre-existing autoimmune diseases or previous immunotherapy-induced irAEs ([@B173]), or under persistent immunosuppression due to chronic viral infections ([@B174]) and allogeneic transplantation ([@B175]), developing preclinical models that incorporate multiple elements relating to tumor origin, patient history, and environment that assist in providing a more informed understanding of the clinical impact of therapeutic combinations will be essential.

As the number of immunotherapeutic targets expands, initiating smarter multi-modal strategies, to provide greater efficacy with lower toxicity will be appealing. Advancement in engineering therapies to have delayed release or greater tissue and cellular specificity have great promise. As mentioned, depletion of intratumoral Tregs without impacting peripheral Tregs would be advantageous for inducing TME-specific modulation of the CD8^+^ to Treg ratio, while avoiding toxicity induced by systemic depletion. Notably, the development of a dual variable domain anti-CTLA-4 antibody, which exhibits an outer tumor antigen-binding site that hides the CTLA-4 binding region of the antibody until reaching the TME has been shown to reduce immunotherapy-induced toxicity without impeding anti-tumor immunity ([@B176]). Similarly, bispecific or trispecific antibodies that target multiple markers upregulated in the TME on both immune cell subsets and the tumor may also lead to greater efficacy ([@B177], [@B178]). One such example, is the bispecific antibody combination targeting OX40 and CTLA-4, which significantly enhanced CD8^+^ T cells and reduced Tregs specifically within the TME, leading to better tumor control than either therapy alone ([@B178]). In addition to modifying the target antigen, antibodies may also be conjugated to biomaterials or nanoparticles, to ensure sustained, local release ([@B179]). Refinement made to antibodies by factoring TME properties, such as pH activation and PD-1 glycosylation ([@B180]--[@B182]), should also significantly improve the specificity and potency of immunotherapies and limit unwanted toxicity.

Future Directions {#s7}
=================

While determining the optimal immunotherapy for an individual TME remains a challenge, encouraging is the range of available strategies to re-educate the immune response against tumor. Refinement of therapeutic targets against cellular and immunomodulatory molecules within the TME are increasing, and their promise for clinical utility is growing. Importantly, greater effort in defining the therapeutic setting where each may be applicable will be essential for clinical success. Since anti-PD-1/PD-L1 has shown value in multiple modalities, examining tumor types where anti-PD-1 activity is limited may yield greatest therapeutic breakthroughs in identifying strategies to remodel inert immune circumstances in the tumor. In deciding on the use of these therapies, a cost-benefit analysis relating to the purported immunotoxicity and likelihood for the immunotherapy strategy to enhance anti-tumor immunity is necessary. This emphasizes a need for rational and selective combination immunotherapies to be utilized within a defined TME in order to re-educate the anti-tumor immune response.
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A2AR

:   A2A adenosine receptor

APCs

:   antigen presenting cells

CSF1

:   colony stimulating factor 1

CSF1R

:   colony stimulating factor 1 receptor

COX

:   cyclooxygenase

CTLA-4

:   cytotoxic T-lymphocyte associated protein 4

dMMR

:   deficient DNA mismatch repair

EZH2

:   enhancer of zeste homolog 2

FLT3L

:   FMS-like tyrosine kinase 3 ligand

IDO

:   indoleamine 2,3-dioxygenase

IFN

:   interferon

irAEs

:   immune-related adverse events

IL

:   interleukin

MAIT

:   mucosal-associated invariant T

MSI-h

:   microsatellite instability-hi

NKT

:   natural killer T

NRP1

:   neuropilin-1

NSCLC

:   non-small cell lung cancer

PDAC

:   pancreatic ductal adenocarcinoma

PD-1

:   programmed death-1

PD-L1

:   programmed death-ligand 1

PMN-MDSC

:   polymorphonuclear myeloid-derived suppressor cells

PTSG2

:   prostaglandin-endoperoxide synthase 2

RCC

:   renal cell carcinoma

Tregs

:   regulatory T cells

TAMs

:   tumor-associated macrophages

TGF

:   transforming growth factor

TILs

:   tumor-infiltrating lymphocytes

TME

:   tumor microenvironment

TNF

:   tumor necrosis factor

VEGF

:   vascular endothelial growth factor.

[^1]: Edited by: Sophie Lucas, Université Catholique de Louvain, Belgium

[^2]: Reviewed by: Connie Jackaman, Curtin University, Australia; Robert J. Canter, University of California, Davis, United States

[^3]: This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

[^4]: †These authors have contributed equally to this work
